James E. Grace

Inhibition of AAK1 Kinase as a Novel Therapeutic Approach to Treat Neuropathic Pain

Walter A. Kostich, Brian D. Hamman, Kumaran Dandapani et al. · Journal of Pharmacology and Experimental Therapeutics · 2016 · 120 citations · Full text

Medicine, Neuroscience, Pharmacology +17

Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

Kan He, Joseph M. Luettgen, Donglu Zhang et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2011 · 97 citations

Medicine, Pharmacokinetics, Pharmacology +8

Development and Validation of a Preclinical Food Effect Model

Kimberley A. Lentz, Megan Quitko, Daniel G. Morgan et al. · Journal of Pharmaceutical Sciences · 2006 · 85 citations

Pharmacy, Nutrition, Nutritional Sciences +5

A Strategy to Minimize Reactive Metabolite Formation: Discovery of (<i>S</i>)-4-(1-Cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a Potent, Orally Bioavailable Corticotropin-Releasing Factor-1 Receptor Antagonist

Richard A. Hartz, Vijay T. Ahuja, Xiaoliang Zhuo et al. · Journal of Medicinal Chemistry · 2009 · 54 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Preclinical Pharmacokinetic and Metabolism of Apixaban, a Potent and Selective Factor Xa Inhibitor.

Kan He, Bing He, James E. Grace et al. · Blood · 2006 · 49 citations

Medicine, Pharmacokinetics, Pharmacology +7